Non-clinical GLP genotoxicity and rodent oral toxicity studies of 6′-hydroxy justicidin B for anti-COVID-19 agent development - 11/11/25
, Seng-Min Back a , Min Seong Jang a , Junguk Choi b , Jihyun Jeon b , Kyong-Cheol Ko c , Yong-Bum Kim a, ⁎
Benvenuto su EM|consulte, il riferimento dei professionisti della salute.
Articolo gratuito.
Si connetta per beneficiarne
Abstract |
Despite the development of Coronavirus Disease 2019 (COVID-19) vaccines, the search for a definitive cure continues. 6′-Hydroxy justicidin B (6′-HJB), found in Justicia procumbens and used in Chinese medicine for its antiviral properties, shows promise as a therapeutic candidate against COVID-19. Nevertheless, it is crucial to establish its safety profile before clinical trials. This study evaluated its safety through non-clinical Good Laboratory Practice genotoxicity and rodent toxicity studies. The results indicated that 6′-HJB is not genotoxic, supporting its safety for future clinical use. The compound exhibited a low risk of DNA damage, a critical concern in drug development. Extensive toxicity studies, including single and repeated oral doses in Sprague Dawley rats, showed that the lethal dose of 6′-HJB exceeded 2000 mg/kg, with no observed adverse effects at this level. Safety data from genotoxicity and rodent toxicity studies strongly support further investigation of 6′-HJB as a novel treatment for COVID-19. 6′-HJB is expected to serve as a promising therapeutic option for overcoming future emerging viral infectious diseases.
Il testo completo di questo articolo è disponibile in PDF.Graphical Abstract |
Highlights |
• | GLP-compliant genotoxicity and toxicity tests established 6′-HJB safety. |
• | 6′-HJB showed no genotoxic effects in regulatory-standard safety assays. |
• | Oral doses up to 2000 mg/kg caused no mortality or adverse findings. |
• | Sprague–Dawley rat studies confirmed non-lethal and non-toxic outcomes. |
• | Results support 6′-HJB as a safe candidate for future clinical development. |
Keywords : COVID-19, 6′-hydroxy justicidin B (6′-HJB), Genotoxicity, Rodent toxicity studies, Good Laboratory Practice (GLP), No-observed-adverse-effect level (NOAEL), Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
Mappa
Vol 192
Articolo 118708- novembre 2025 Ritorno al numero
Articolo precedente
- Modified Zn-MOF multifunctional nanoparticles for combination therapy of DN and exploratory study of the nephroprotective effect
- Yuna Tong, Xiuxiu Li, Yuxuan Zhu, Xiaohui Liao, Ling Zhang
- Manganese porphyrin [MnTE-2-PyP]5+ improves maternal and offspring glycemic homeostasis, placental morphology, and redox balance in diabetic pregnant rats
- Adriana Lopes da Silva, Bianca Reis Santos, Luciano Cardoso Santos, Jeane Martinha dos Anjos Cordeiro, Erikles Macêdo Barbosa, Brenda Geovana Campos Martins, Cibele Luz Oliveira, Emilly Oliveira Santos, Natália Panhoca Rodrigues, Rodrigo Oliveira Malheiros, Júlio Santos Rebouças, Gilson DeFreitas-Silva, Daniel de Assis Santos, Stephanie Carvalho Borges, Mário Sérgio Lima de Lavor, Estela Bevilacqua, Juneo Freitas Silva
Benvenuto su EM|consulte, il riferimento dei professionisti della salute.